JP2017507945A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507945A5 JP2017507945A5 JP2016554212A JP2016554212A JP2017507945A5 JP 2017507945 A5 JP2017507945 A5 JP 2017507945A5 JP 2016554212 A JP2016554212 A JP 2016554212A JP 2016554212 A JP2016554212 A JP 2016554212A JP 2017507945 A5 JP2017507945 A5 JP 2017507945A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- hvr
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 182
- 238000000034 method Methods 0.000 claims description 94
- 101000863884 Homo sapiens Sialic acid-binding Ig-like lectin 8 Proteins 0.000 claims description 86
- 102000051056 human SIGLEC8 Human genes 0.000 claims description 69
- 239000000203 mixture Substances 0.000 claims description 51
- 208000024891 symptom Diseases 0.000 claims description 51
- 206010009137 Chronic sinusitis Diseases 0.000 claims description 39
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 39
- 239000000556 agonist Substances 0.000 claims description 35
- 208000038004 exacerbated respiratory disease Diseases 0.000 claims description 30
- 230000001771 impaired effect Effects 0.000 claims description 25
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 21
- 229930182474 N-glycoside Natural products 0.000 claims description 21
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 21
- 206010011224 Cough Diseases 0.000 claims description 20
- 150000001720 carbohydrates Chemical group 0.000 claims description 20
- 230000007794 irritation Effects 0.000 claims description 20
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 19
- 208000006673 asthma Diseases 0.000 claims description 19
- 102100029964 Sialic acid-binding Ig-like lectin 8 Human genes 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 206010003645 Atopy Diseases 0.000 claims description 16
- 230000003915 cell function Effects 0.000 claims description 16
- 208000000592 Nasal Polyps Diseases 0.000 claims description 15
- 206010036790 Productive cough Diseases 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 208000024794 sputum Diseases 0.000 claims description 15
- 210000003802 sputum Anatomy 0.000 claims description 15
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 210000003979 eosinophil Anatomy 0.000 claims description 13
- 208000015768 polyposis Diseases 0.000 claims description 13
- 206010039101 Rhinorrhoea Diseases 0.000 claims description 12
- 208000010753 nasal discharge Diseases 0.000 claims description 12
- 208000028347 Sinus disease Diseases 0.000 claims description 11
- 201000010659 intrinsic asthma Diseases 0.000 claims description 11
- 206010014950 Eosinophilia Diseases 0.000 claims description 9
- 210000000822 natural killer cell Anatomy 0.000 claims description 9
- 230000002085 persistent effect Effects 0.000 claims description 9
- 206010006326 Breath odour Diseases 0.000 claims description 8
- 206010016059 Facial pain Diseases 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 206010028735 Nasal congestion Diseases 0.000 claims description 8
- 206010052437 Nasal discomfort Diseases 0.000 claims description 8
- 206010028748 Nasal obstruction Diseases 0.000 claims description 8
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 8
- 208000032140 Sleepiness Diseases 0.000 claims description 8
- 206010041349 Somnolence Diseases 0.000 claims description 8
- 208000027744 congestion Diseases 0.000 claims description 8
- 208000002173 dizziness Diseases 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 208000004371 toothache Diseases 0.000 claims description 8
- 208000037874 Asthma exacerbation Diseases 0.000 claims description 7
- 102000003886 Glycoproteins Human genes 0.000 claims description 7
- 108090000288 Glycoproteins Proteins 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 7
- 208000016366 nasal cavity polyp Diseases 0.000 claims description 7
- 229920001542 oligosaccharide Polymers 0.000 claims description 7
- 150000002482 oligosaccharides Chemical class 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 150000003431 steroids Chemical class 0.000 claims description 7
- 230000009885 systemic effect Effects 0.000 claims description 7
- 208000032139 Halitosis Diseases 0.000 claims description 6
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 6
- 206010025482 malaise Diseases 0.000 claims description 6
- 230000035945 sensitivity Effects 0.000 claims description 6
- 208000019116 sleep disease Diseases 0.000 claims description 6
- 208000020685 sleep-wake disease Diseases 0.000 claims description 6
- 206010011703 Cyanosis Diseases 0.000 claims description 4
- 208000000059 Dyspnea Diseases 0.000 claims description 4
- 206010013975 Dyspnoeas Diseases 0.000 claims description 4
- 208000037656 Respiratory Sounds Diseases 0.000 claims description 4
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 4
- 206010047924 Wheezing Diseases 0.000 claims description 4
- 208000013116 chronic cough Diseases 0.000 claims description 4
- 208000013220 shortness of breath Diseases 0.000 claims description 4
- 230000004580 weight loss Effects 0.000 claims description 4
- 206010008469 Chest discomfort Diseases 0.000 claims description 3
- 230000000779 depleting effect Effects 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 230000020279 natural killer cell cytokine production Effects 0.000 claims description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 206010014020 Ear pain Diseases 0.000 claims 4
- 206010070488 Upper-airway cough syndrome Diseases 0.000 claims 4
- 230000037418 vocal dysfunction Effects 0.000 claims 4
- 238000013313 FeNO test Methods 0.000 claims 2
- 238000012360 testing method Methods 0.000 claims 2
- 206010003497 Asphyxia Diseases 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 230000004199 lung function Effects 0.000 claims 1
- 238000013123 lung function test Methods 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 238000013125 spirometry Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 230000002265 prevention Effects 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 230000001270 agonistic effect Effects 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461946407P | 2014-02-28 | 2014-02-28 | |
| US61/946,407 | 2014-02-28 | ||
| PCT/US2015/018188 WO2015131155A1 (en) | 2014-02-28 | 2015-02-27 | Methods and compositions for treating siglec-8 associated diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021003944A Division JP2021054866A (ja) | 2014-02-28 | 2021-01-14 | シグレック−８関連疾患を処置するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017507945A JP2017507945A (ja) | 2017-03-23 |
| JP2017507945A5 true JP2017507945A5 (OSRAM) | 2018-04-12 |
| JP6825909B2 JP6825909B2 (ja) | 2021-02-03 |
Family
ID=54009691
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016554212A Active JP6825909B2 (ja) | 2014-02-28 | 2015-02-27 | シグレック−８関連疾患を処置するための方法および組成物 |
| JP2021003944A Pending JP2021054866A (ja) | 2014-02-28 | 2021-01-14 | シグレック−８関連疾患を処置するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021003944A Pending JP2021054866A (ja) | 2014-02-28 | 2021-01-14 | シグレック−８関連疾患を処置するための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10183996B2 (OSRAM) |
| EP (2) | EP4014995A1 (OSRAM) |
| JP (2) | JP6825909B2 (OSRAM) |
| AU (2) | AU2015222757B2 (OSRAM) |
| CA (1) | CA2939931C (OSRAM) |
| DK (1) | DK3110446T3 (OSRAM) |
| WO (1) | WO2015131155A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210125114A (ko) * | 2013-12-09 | 2021-10-15 | 알라코스 인크. | 항-Siglec-8 항체 및 그의 사용 방법 |
| CA2939931C (en) | 2014-02-28 | 2025-04-22 | Allakos Inc. | METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SIGLEC8 |
| AU2016278239B9 (en) * | 2015-06-17 | 2022-08-11 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
| US10604577B2 (en) * | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
| WO2018129400A1 (en) * | 2017-01-06 | 2018-07-12 | Allakos Inc. | Methods and compositions for treating chronic obstructive pulmonary disorder |
| EP3618872A4 (en) * | 2017-05-05 | 2021-06-30 | Allakos Inc. | METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATORY STOMACH AND INTESTINAL DISEASES |
| EA201992626A1 (ru) * | 2017-05-05 | 2020-04-24 | Аллакос Инк. | Способы и композиции для лечения аллергических заболеваний глаз |
| EP3732194A1 (en) * | 2017-12-29 | 2020-11-04 | Cornell University | Gene therapy for eosinophilic disorders |
| CA3226165A1 (en) * | 2018-02-09 | 2019-08-15 | Genentech, Inc. | Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases |
| WO2019213468A1 (en) * | 2018-05-04 | 2019-11-07 | Allakos Inc. | Methods and compositions for treating chronic urticaria |
| JP7546924B2 (ja) * | 2019-03-01 | 2024-09-09 | 国立大学法人 筑波大学 | アレルギー疾患を処置することに用いるための組成物 |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5891693A (en) | 1990-01-25 | 1999-04-06 | Alusuisse Holdings A.G. | Recombinant DNA methods vectors and host cells |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
| US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| JPH08500962A (ja) | 1992-02-06 | 1996-02-06 | クリエイティブ バイオモレキュルズ，インコーポレイテッド | 癌マーカー用生物合成結合蛋白質 |
| AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| EP1005870B1 (en) | 1992-11-13 | 2009-01-21 | Biogen Idec Inc. | Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
| US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6027888A (en) | 1996-04-05 | 2000-02-22 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells |
| DE19619068A1 (de) | 1996-05-13 | 1997-11-27 | Siemens Ag | Vorrichtung zur Überwachung des Transportprozesses von flachen Sendungen |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
| ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
| ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PT2180007E (pt) | 1998-04-20 | 2013-11-25 | Roche Glycart Ag | Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR101155191B1 (ko) | 1999-01-15 | 2012-06-13 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
| WO2001066126A1 (en) * | 2000-03-07 | 2001-09-13 | Smithkline Beecham Corporation | Sialoadhesin factor-2 antibodies |
| US20030092091A1 (en) | 2000-03-07 | 2003-05-15 | Abrahamson Julie A. | Sialoadhesin factor-2 antibodies |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US20020106738A1 (en) | 2000-10-06 | 2002-08-08 | George Foussias | Novel Siglec gene |
| DK1355919T3 (da) | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molekyler med længere halveringstider, sammensætninger og anvendelser deraf |
| NZ603111A (en) | 2001-08-03 | 2014-05-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
| JPWO2003085119A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物のＦｃγ受容体ＩＩＩａに対する結合活性を高める方法 |
| EP1500400A4 (en) | 2002-04-09 | 2006-10-11 | Kyowa Hakko Kogyo Kk | MEDICAMENT CONTAINING ANTIBODY COMPOSITION |
| AU2003236020B2 (en) | 2002-04-09 | 2009-03-19 | Kyowa Hakko Kirin Co., Ltd. | Cell with depression or deletion of the activity of protein participating in GDP-fucose transport |
| JPWO2003085118A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
| US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| DE60332957D1 (de) | 2002-12-16 | 2010-07-22 | Genentech Inc | Immunoglobulinvarianten und deren verwendungen |
| EP1688439A4 (en) | 2003-10-08 | 2007-12-19 | Kyowa Hakko Kogyo Kk | COMPOSITION OF CONDENSED PROTEINS |
| US20070134759A1 (en) | 2003-10-09 | 2007-06-14 | Harue Nishiya | Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase |
| JP4653109B2 (ja) | 2003-11-05 | 2011-03-16 | ロシュ グリクアート アクチェンゲゼルシャフト | 高められたＦｃレセプター結合親和性及びエフェクター機能をもつＣＤ２０抗体 |
| JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| JP4782700B2 (ja) | 2004-01-20 | 2011-09-28 | カロバイオス ファーマシューティカルズ インコーポレイティッド | 最低限必須な結合決定基を用いた抗体特異性の移入 |
| WO2005116088A2 (en) | 2004-05-25 | 2005-12-08 | The Johns Hopkins University | Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells |
| EP1824987B1 (en) | 2004-11-16 | 2013-08-21 | KaloBios Pharmaceuticals, Inc. | Immunoglobulin variable region cassette exchange |
| EP1951740B1 (en) | 2005-11-10 | 2014-07-16 | James Paulson | High affinity siglec ligands |
| US20070134259A1 (en) | 2005-11-21 | 2007-06-14 | David Bundle | Methods and compositions for pharmacologially controlled targeted immunotherapy |
| RS54163B1 (sr) | 2006-05-30 | 2015-12-31 | Genentech Inc. | Anti-cd22 antitela, njihovi imunokonjugati i njihova upotreba |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| EP2666787B1 (en) | 2007-05-31 | 2022-02-09 | Genmab A/S | STABLE IgG4 ANTIBODIES |
| CA2975228C (en) | 2008-05-02 | 2020-07-21 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| EP3153524B1 (en) | 2008-12-03 | 2025-04-23 | Genmab A/S | Antibody variants having modifications in the constant region |
| PL2470671T3 (pl) | 2009-08-28 | 2015-05-29 | Regeneron Pharma | Przeciwciała antykinowe wiążące się z wieloma chemokinami CC |
| JP5746183B2 (ja) | 2009-09-22 | 2015-07-08 | プロビオゲン アーゲー | 特定のグリカン構造を含有する分子を生成する方法 |
| CN103153339B (zh) | 2010-05-27 | 2021-05-04 | 根马布股份公司 | 针对her2表位的单克隆抗体 |
| US8586044B2 (en) | 2010-05-28 | 2013-11-19 | Northwestern University | Treatment of chronic pelvic pain syndrome |
| EP2465873A1 (en) * | 2010-12-16 | 2012-06-20 | Deutsches Rheuma-Forschungszentrum Berlin | Eosinophils as a therapeutic target |
| US9260756B2 (en) | 2012-02-24 | 2016-02-16 | Children's Hospital Medical Center | Esophageal microRNA expression profiles in eosinophilic esophagitis |
| KR20150044680A (ko) | 2013-10-17 | 2015-04-27 | 인하대학교 산학협력단 | 항-Siglec-8 항체 또는 항-Siglec-F 항체를 포함하는 알러지 질환의 예방 또는 치료용 조성물 |
| KR101567758B1 (ko) | 2013-10-17 | 2015-11-11 | 인하대학교 산학협력단 | 항-Siglec-8 항체 또는 항-Siglec-F 항체, 및 항-IL-33 항체를 포함하는 알러지 질환의 예방 또는 치료용 조성물 |
| KR20210125114A (ko) | 2013-12-09 | 2021-10-15 | 알라코스 인크. | 항-Siglec-8 항체 및 그의 사용 방법 |
| CA2939931C (en) | 2014-02-28 | 2025-04-22 | Allakos Inc. | METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SIGLEC8 |
| AU2016278239B9 (en) | 2015-06-17 | 2022-08-11 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
| US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
| WO2018129400A1 (en) | 2017-01-06 | 2018-07-12 | Allakos Inc. | Methods and compositions for treating chronic obstructive pulmonary disorder |
-
2015
- 2015-02-27 CA CA2939931A patent/CA2939931C/en active Active
- 2015-02-27 US US15/121,756 patent/US10183996B2/en active Active
- 2015-02-27 DK DK15755175.5T patent/DK3110446T3/da active
- 2015-02-27 EP EP21204280.8A patent/EP4014995A1/en not_active Withdrawn
- 2015-02-27 AU AU2015222757A patent/AU2015222757B2/en active Active
- 2015-02-27 JP JP2016554212A patent/JP6825909B2/ja active Active
- 2015-02-27 EP EP15755175.5A patent/EP3110446B1/en active Active
- 2015-02-27 WO PCT/US2015/018188 patent/WO2015131155A1/en not_active Ceased
-
2021
- 2021-01-07 AU AU2021200075A patent/AU2021200075A1/en not_active Abandoned
- 2021-01-14 JP JP2021003944A patent/JP2021054866A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507945A5 (OSRAM) | ||
| JP7695298B2 (ja) | Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法 | |
| AU2018253118B2 (en) | Treatment of asthma with anti-TSLP antibody | |
| CA2918105C (en) | Methods for reducing exacerbation rates of asthma using benralizumab | |
| JP2018505177A5 (OSRAM) | ||
| JP2018525332A5 (OSRAM) | ||
| CN110799543A (zh) | 肝细胞癌的免疫治疗 | |
| HK1225302A1 (en) | Methods for reducing exacerbation rates of asthma using benralizumab | |
| CN104684552A (zh) | 组合及其用途 | |
| CN107108727A (zh) | 对人vegf‑a有异常强的结合亲和力并具有与人vegf‑b的交叉反应性的抗人vegf抗体 | |
| JP2025122028A (ja) | Ｉｌ－３３アンタゴニストを投与することにより喘息を治療するまたは予防するための方法 | |
| JP2018533569A5 (OSRAM) | ||
| EP3520811B1 (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab | |
| US20240092875A1 (en) | Sars-cov-2 antibodies for treatment and prevention of covid-19 | |
| JP2020504135A5 (OSRAM) | ||
| EP3033103B1 (en) | Methods for improving asthma symptoms using benralizumab | |
| AU2023278017A1 (en) | Combination therapies for the treatment of cancer | |
| CN119584995A (zh) | 组合疗法 | |
| JPWO2019169015A5 (OSRAM) | ||
| JPWO2021026021A5 (OSRAM) | ||
| AU2023278019A1 (en) | Combination therapies for the treatment of non-small cell lung cancer | |
| JPWO2022034044A5 (OSRAM) | ||
| JP2024542777A (ja) | 多発血管炎、好酸球増多症候群、好酸球増多症候群、鼻ポリープを伴う慢性副鼻腔炎（ｃｒｓｗｎｐ）又は鼻ポリープを伴わない慢性副鼻腔炎（ｃｒｓｓｎｐ）の処置における使用のためのインターロイキン５結合タンパク質投与レジメン | |
| HK40035226A (en) | Methods for reducing exacerbation rates of asthma using benralizumab |